Vimarsana
Biggest News Aggregation in the World

Page 6 - Altimmune News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Altimmune. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Altimmune Today - Breaking & Trending Today

Altimmune (NASDAQ:ALT) Sees Strong Trading Volume - Vimarsana News

Altimmune (NASDAQ:ALT) Sees Strong Trading Volume

Altimmune, Inc. (NASDAQ:ALT – Get Free Report) shares saw an uptick in trading volume on Wednesday . 2,945,008 shares were traded during mid-day trading, a decline of 14% from the previous session’s volume of 3,413,630 shares.The stock last traded at $11.87 and had previously closed at $10.97. Analyst Upgrades and Downgrades A number of brokerages […]

Traders Buy Large Volume of Call Options on Altimmune (NASDAQ:ALT) - Vimarsana News

Traders Buy Large Volume of Call Options on Altimmune (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT – Get Free Report) saw unusually large options trading on Tuesday. Traders bought 7,433 call options on the company. This is an increase of approximately 54% compared to the average daily volume of 4,842 call options. Altimmune Stock Performance Shares of ALT stock traded up $0.87 on Tuesday, hitting $10.14. The company […]

Source: wkrb13.com
Pfizer's Obesity Pill Disappointed. Biotech Rivals Are Rubbing Their Hands. - Vimarsana News

Pfizer's Obesity Pill Disappointed. Biotech Rivals Are Rubbing Their Hands.

Pfizer expects the market for new obesity pills to be $90 billion per year. Lilly, Novo, and many biotechs hope to claim chunks of it.

Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end - Vimarsana News

Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end

Companies — both big and small — are hoping to grab a piece of the lucrative anti-obesity drug market. Piper Sandler counts 78 agents in development.

Source: cnbc.com
Altimmune to Participate at Two Upcoming Investor - Vimarsana News

Altimmune to Participate at Two Upcoming Investor

GAITHERSBURG, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that...